Systematic Review of Therapies for Stable Coronary Artery Disease in Diabetic Patients

Annals of Thoracic Surgery

Volumn 100, Issue 6, 2015, Pages 2383-2397

  Luthra, Suvitesh ^a   Leiva Juárez, Miguel M ^a   Taggart, David P ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

BARE METAL STENT; CARDIOVASCULAR MORTALITY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; DRUG ELUTING STENT; HEART DEATH; HEART MUSCLE REVASCULARIZATION; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; SYNTAX SCORE; SYSTEMATIC REVIEW; COMPLICATION; DIABETIC ANGIOPATHIES; STENT;

CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHIES; HUMANS; MYOCARDIAL REVASCULARIZATION; PERCUTANEOUS CORONARY INTERVENTION; STENTS;

EID: 84961886744     PISSN: 00034975     EISSN: 15526259     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2015.07.005     Document Type: Review

References (50)

1. 1 Geiss, L.S., Herman, W.H., Smith, P.J., Mortality in non-insulin-dependent diabetes. 2nd ed., 1995, National Diabetes Data Group, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
2. 2 American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 31 (2008), 596–615.
3. 3 Cowie, C.C., Rust, K.F., Ford, E.S., et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 32 (2009), 287–294.
4. 4 Stein, B., Weintraub, W.S., Gebhart, S.P., et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 91 (1995), 979–989.
5. 5 Elezi, S., Kastrati, A., Pache, J., et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 32 (1998), 1866–1873.
6. 6 Du, X., Edelstein, D., Obici, S., et al. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest 116 (2006), 1071–1080.
7. 7 Orasanu, G., Plutzky, J., The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol 53:Suppl (2009), 35–42.
8. 8 Sabaté, M., Jiménez-Quevedo, P., Angiolillo, D.J., et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the Diabetes and Sirolimus-Eluting Stent (DIABETES) trial. Circulation 112 (2005), 2175–2183.
9. 9 Mieres, J., Fernandez-Pereira, C., Risau, G., et al. One-year outcome of patients with diabetes mellitus after percutaneous coronary intervention with three different revascularization strategies: results from the Diabetic Argentina Registry (DEAR). Cardiovasc Revasc Med 13 (2012), 265–271.
10. 10 Sinning, J.M., Baumgart, D., Werner, N., et al. Five-year results of the multicenter randomized controlled open-label study of the CYPHER Sirolimus-Eluting Stent in the Treatment of Diabetic Patients with De Novo Native Coronary Artery Lesions (SCORPIUS) study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. Am Heart J 163 (2012), 446–453.
11. 11 Serruys, P.W., Ong, A.T., van Herwerden, L.A., et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 46 (2005), 575–581.
12. 12 BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol 49 (2007), 1600–1606.
13. 13 The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 335 (1996), 217–225.
14. 14 Kapur, A., Malik, I.S., Bagger, J.P., et al. The Coronary Artery Revascularisation in Diabetes (CARDiA) trial: background, aims, and design. Am Heart J 149 (2005), 13–19.
15. 15 Kapur, A., Hall, R.J., Malik, I.S., et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDiA (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol 55 (2010), 432–440.
16. 16 Banning, A.P., Westaby, S., Morice, M.C., et al. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol 55 (2010), 1067–1075.
17. 17 Kappetein, A.P., Head, S.J., Morice, M.C., et al. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg 43 (2013), 1006–1013.
18. 18 Farkouh, M.E., Domanski, M., Sleeper, L.A., et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 367 (2012), 2375–2384.
19. 19 Farkouh, M.E., Dangas, G., Leon, M.B., et al. Design of the Future Revascularization Evaluation in Patients With Diabetes Mellitus: optimal management of multivessel disease (FREEDOM) trial. Am Heart J 155 (2008), 215–223.
20. 20 Kamalesh, M., Sharp, T.G., Tang, X.C., et al. Percutaneous coronary intervention versus coronary bypass surgery in United States veterans with diabetes. J Am Coll Cardiol 61 (2013), 808–816.
21. 21 Frye, R.L., August, P., Brooks, M.M., et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 360 (2009), 2503–2515.
22. 22 Lima, E.G., Hueb, W., Garcia, R.M., et al. Impact of diabetes on 10-year outcomes of patients with multivessel coronary artery disease in the Medicine, Angioplasty, or Surgery Study II (MASS II) trial. Am Heart J 166 (2013), 250–257.
23. 23 Brooks, M.M., Chaitman, B.R., Nesto, R.W., et al. Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation 126 (2012), 2115–2124.
24. 24 Chung, S.C., Hlatky, M.A., Faxon, D., et al. The effect of age on clinical outcomes and health status BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes). J Am Coll Cardiol 58 (2011), 810–819.
25. 25 Beohar, N., Sansing, V.V., Davis, A.M., et al. Race/ethnic disparities in risk factor control and survival in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am J Cardiol 112 (2013), 1298–1305.
26. 26 Tamis-Holland, J.E., Lu, J., Korytkowski, M., et al. Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: a report from the BARI 2D trial (Bypass Angioplasty Revascularization Investigation 2 Diabetes). J Am Coll Cardiol 61 (2013), 1767–1776.
27. 27 Dagenais, G.R., Lu, J., Faxon, D.P., et al. Prognostic impact of the presence and absence of angina on mortality and cardiovascular outcomes in patients with type 2 diabetes and stable coronary artery disease: results from the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial. J Am Coll Cardiol 61 (2013), 702–711.
28. 28 Serruys, P.W., Morice, M.C., Kappetein, A.P., et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360 (2009), 961–972.
29. 29 BARI Investigators. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol 35 (2000), 1122–1129.
30. 30 The BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 96 (1997), 1761–1769.
31. 31 Boden, W.E., O'Rourke, R.A., Teo, K.K., et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356 (2007), 1503–1516.
32. 32 Boden, W.E., O'Rourke, R.A., Teo, K.K., et al. Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular endpoints in patients with stable coronary artery disease (from the COURAGE trial). Am J Cardiol 104 (2009), 1–4.
33. 33 Babapulle, M.N., Joseph, L., Bélisle, P., et al. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 364 (2004), 583–591.
34. 34 Stone, G.W., Ellis, S.G., Cox, D.A., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004), 221–231.
35. 35 Hlatky, M.A., Boothroyd, D.B., Bravata, D.M., et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 373 (2009), 1190–1197.
36. 36 Dinneen, S.F., Gerstein, H.C., The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 157 (1997), 1413–1418.
37. 37 Preiss, D., Sattar, N., McMurray, J.J., A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. Am Heart J 161 (2011), 210–219.
38. 38 Duckworth, W., Abraira, C., Moritz, T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009), 129–139.
39. 39 Patel, A., MacMahon, S., Chalmers, J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
40. 40 Gerstein, H.C., Miller, M.E., Byington, R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008), 2545–2559.
41. 41 Erdmann, E., Dormandy, J.A., Charbonnel, B., et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study. J Am Coll Cardiol 49 (2007), 1772–1780.
42. 42 Mazzone, T., Meyer, P.M., Feinstein, S.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296 (2006), 2572–2581.
43. 43 Nissen, S.E., Nicholls, S.J., Wolski, K., et al. Comparison of pioglitazone versus glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299 (2008), 1561–1573.
44. 44 Sheu, W.H., Ou, H.C., Chou, F.P., et al. Rosiglitazone inhibits endothelial proliferation and angiogenesis. Life Sci 78 (2006), 1520–1528.
45. 45 Wijns, W., Kolh, P., Danchin, N., et al. Guidelines on myocardial revascularization. Eur Heart J 31 (2010), 2501–2555.
46. 46 Levine, G.N., Bates, E.R., Blankenship, J.C., et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58 (2011), e44–122.
47. 47 Chieffo, A., Park, S.J., Valgimigli, M., et al. Favorable long-term outcome after drug-eluting stent implantation in nonbifurcation lesions that involve unprotected left main coronary artery: a multicenter registry. Circulation 116 (2007), 158–162.
48. 48 Tamburino, C., Capranzano, P., Capodanno, D., et al. Plaque distribution patterns in distal left main coronary artery to predict outcomes after stent implantation. J Am Coll Cardiol Intv 3 (2010), 624–631.
49. 49 Lee, M.S., Kapoor, N., Jamal, F., et al. Comparison of coronary artery bypass surgery with percutaneous coronary intervention with drug-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol 47 (2006), 864–870.
50. 50 Hakeem, A., Garg, N., Bhatti, S., et al. Effectiveness of percutaneous coronary intervention with drug-eluting stents compared with bypass surgery in diabetics with multivessel coronary disease: comprehensive systematic review and meta-analysis of randomized clinical data. J Am Heart Assoc, 2, 2013, e000354.